Related Experiment Videos

HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway

B P Zhou1, M C Hu, S A Miller

  • 1Department of Molecular and Cellular Oncology, Breast Cancer Basic Research Program, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

Insights

Overexpression of HER2/neu in cancer leads to resistance against tumor necrosis factor (TNF) by activating the Akt/NF-kappaB pathway. Blocking this pathway sensitizes cancer cells to TNF-induced apoptosis, enhancing immune defense against tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • HER2/neu overexpression is linked to poor survival in breast and ovarian cancers.
  • HER2/neu confers resistance to tumor necrosis factor (TNF)-induced apoptosis, aiding cancer cell immune evasion.
  • The molecular mechanisms underlying HER2/neu-mediated TNF resistance remain unclear.

Purpose of the Study:

  • To elucidate the mechanism by which HER2/neu overexpression confers resistance to TNF.
  • To investigate the role of the Akt and NF-kappaB signaling pathways in HER2/neu-induced TNF resistance.

Main Methods:

  • Constitutive activation of Akt and NF-kappaB by HER2/neu was assessed without external stimulation.
  • Dominant-negative Akt was used to block the Akt pathway in HER2/neu-overexpressing cells.
  • Inhibition of IkappaB kinases, IkappaB phosphorylation, and NF-kappaB activation was measured.

Main Results:

  • HER2/neu constitutively activates Akt and NF-kappaB signaling pathways.
  • Blocking the Akt pathway sensitizes HER2/neu-overexpressing cells to TNF-induced apoptosis.
  • Inhibition of the Akt pathway leads to reduced IkappaB kinase activity, IkappaB phosphorylation, and NF-kappaB activation.

Conclusions:

  • HER2/neu constitutively activates the Akt/NF-kappaB anti-apoptotic cascade.
  • This activation confers resistance to TNF, promoting cancer cell survival.
  • Targeting the Akt/NF-kappaB pathway may restore TNF sensitivity and enhance anti-cancer immune responses.

Related Concept Videos